Polymun Scientific brings liposome manufacturing technology to BIO-Europe

Polymun Scientific brings liposome manufacturing technology to BIO-Europe


Press Release | Polymun Scientific Immunbiologische Forschung GmbH

OCTOBER 29, 2014

Klosterneuburg, Austria: – Specialist biopharmaceutical developer and manufacturer Polymun Scientific has announced it will attend November’s BIO-Europe event in Frankfurt.

Polymun will share the LISA (Life Science Austria) podium, Stand 074, with several other of the country’s innovative life sciences companies.

The family-owned CMO is planning to use its presence at Frankfurt to showcase its high quality mammalian and microbial cell manufacturing technologies.

Liposomal formulation

The company has pioneered a liposome manufacturing technology in order to optimize the production of liposomal formulations at industrial scale.

“We are able to apply this liposomal formulation drug delivery platform to all kinds of pharmaceutically active ingredients,” explained Polymun CEO, Dr. Dietmar Katinger, who will attend BIO-Europe along with the company’s Executive Director and Head of Regulatory Affairs, Dr. Thomas Hemetsberger.

cGMP biopharma partners

“We hope to use the conference to meet new partners that can take advantage of the technologies and capabilities that we now offer,” said Dr. Katinger.

Dr. Katinger said Polymun would use BIO-Europe’s Partnering ONE system to arrange a series of meetings during 3-4 November.

“We also have new cGMP production capabilities to offer, now that we have achieved FDA acceptance, following their inspection of our facilities this time last year,” Dr. Katinger added.

About Polymun Scientific

The family-owned company Polymun Scientific GmbH was founded in 1992. Its core activities are contract development and manufacturing of biopharmaceuticals as well as liposomal formulations of APIs and vaccine antigens.

The core competence of Polymun is GMP-compliant biopharmaceutical manufacturing using mammalian and microbial cell technology. Polymun offers all steps from the gene to clinical grade material for innovator and generic products for supply of all clinical phases as well as market supply.
Polymun operates in accordance with current GMP guidelines and holds an Austrian production license thus meeting all EU requirements for drug manufacturing.

The Polymun team numbers about 60 highly qualified scientists, technologists and support staff of whom almost half hold academic qualifications.

Polymun actively encourages innovation and creativity among its people, with a mission to be a flexible partner focused on the requirements of clients. The company can custom design entirely new projects as well as extra elements needed to complete existing processes.

GMP-compliance and industrial applicability are central to all operations, with contract manufacturing including preparation of IMPD and CMC documents. Polymun is also able to support planning of phase I-III clinical trials.

About BIO-Europe Autumn 2014

The annual BIO-Europe is EBD Group’s flagship partnering conference for the biopharmaceutical and life sciences industries.

The 2014 BIO-Europe event is being held on November 3-5at the Portalhaus Messe exhibition center in Frankfurt, Germany,and marks the 20th anniversary of the event.

BIO-Europe has been running since 2005 and consistently attracts top international executives from established and emerging pharma and biotech companies, along with academic researchers and private investors including venture capital and private equity and organizations developing companion diagnostics.

More than 3,200 delegates representing almost 1,850 companies from 56 countries attended the 19th annual BIO-Europe conference held in Vienna, Austria.The 2013 event also featured more than 180 presentations and 18 workshops or panels. This represented more than ten per cent growth over the previous year.

The event is organised by EBD Group, whose sophisticated web-based partnering ONE system was last year used to facilitate almost 18,000 one-to-one meetings, with some 3,600 licensing opportunities posted.

More information at: http://www.ebdgroup.com/bioeurope/index.php

Media Contact

Dr. Dietmar Katinger, CEO, Polymun Scientific GmbH
Tel: +43 2243 25060 300
Email: office@polymun.com


Click on Polymun Scientific brings liposome manufacturing technology to BIO-Europe for more information.
Click on Polymun Scientific to contact the company directly.

Supplier Information
Supplier: Polymun Scientific Immunbiologische Forschung GmbH
Address: Donaustrasse 99, 3400 Klosterneuburg, Austria
Tel: +43 2243 25060 300
Fax: +43 2243 25060 399
Website: www.polymun.com/

Comments are closed.